Technical Analysis for MRTX - Mirati Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Down |
| Historical MRTX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Support | Bullish | 0.00% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
| Spinning Top | Other | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -0.77% | |
| Outside Day | Range Expansion | -0.77% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -3.42% | |
| Inside Day | Range Contraction | -3.42% | |
| MACD Bearish Signal Line Cross | Bearish | -2.09% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -2.09% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 12/01/2020
- Sector: Healthcare
- Industry: Biotechnology
Mirati Therapeutics Inc., a biopharmaceutical company, engages in the development of therapeutics for the cancer treatment. Its lead program in clinical development is MGCD265, a multi-targeted small molecule kinase inhibitor for treatment of oncology patients with solid tumors. The company also evaluates development opportunities in oncology for mocetinostat, a spectrum-selective HDAC inhibitor for the treatment of patients with myelodysplastic syndrome or lymphoma; and MGCD516, a kinase inhibitor with a target profile for the treatment of patients with non-small cell lung cancer and other solid tumors. Mirati Therapeutics Inc. is headquartered in San Diego, California.
Medicine Biopharmaceutical Cancer Chemical Compounds Oncology Solid Tumors Non Small Cell Lung Cancer Lymphoma Cancer Treatment Targeted Therapy Myelodysplastic Syndrome Bemcentinib
Medicine Biopharmaceutical Cancer Chemical Compounds Oncology Solid Tumors Non Small Cell Lung Cancer Lymphoma Cancer Treatment Targeted Therapy Myelodysplastic Syndrome Bemcentinib
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 132.59 |
| 52 Week Low | 66.01 |
| Average Volume | 482,348 |
| 200-Day Moving Average | 94.97 |
| 50-Day Moving Average | 105.14 |
| 20-Day Moving Average | 113.80 |
| 10-Day Moving Average | 116.04 |
| Average True Range | 5.35 |
| ADX | 19.94 |
| +DI | 17.87 |
| -DI | 13.56 |
| Chandelier Exit (Long, 3 ATRs ) | 105.84 |
| Chandelier Exit (Short, 3 ATRs ) | 114.82 |
| Upper Bollinger Band | 123.38 |
| Lower Bollinger Band | 104.22 |
| Percent B (%b) | 0.56 |
| BandWidth | 16.83 |
| MACD Line | 3.75 |
| MACD Signal Line | 4.23 |
| MACD Histogram | -0.4865 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 120.23 | ||||
| Resistance 3 (R3) | 120.38 | 118.77 | 119.34 | ||
| Resistance 2 (R2) | 118.77 | 117.42 | 118.69 | 119.05 | |
| Resistance 1 (R1) | 116.85 | 116.59 | 116.05 | 116.70 | 118.75 |
| Pivot Point | 115.24 | 115.24 | 114.84 | 115.16 | 115.24 |
| Support 1 (S1) | 113.32 | 113.89 | 112.52 | 113.17 | 111.11 |
| Support 2 (S2) | 111.71 | 113.06 | 111.63 | 110.81 | |
| Support 3 (S3) | 109.79 | 111.71 | 110.52 | ||
| Support 4 (S4) | 109.64 |
